{"filing":{"accession_number":"0001437749-26-025793","cik":"0001668243","ticker":"URGN","company_name":"UroGen Pharma Ltd.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"urgn20260730_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/urgn20260730_8k.htm"},"events":[{"id":24852,"run_id":22529,"accession_number":"0001437749-26-025793","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing UroGen's Q2 2026 financial results, including total revenue of $72.5 million (up from $24.2 million in Q2 2025), ZUSDURI product revenue of $50.4 million with 73% quarter-over-quarter growth, and a net loss of $14.4 million. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's lead product.","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25542,"accession_number":"0001437749-26-025793","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing UroGen's Q2 2026 financial results, including total revenue of $72.5 million (up from $24.2 million in Q2 2025), ZUSDURI product revenue of $50.4 million with 73% quarter-over-quarter growth, and a net loss of $14.4 million. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's lead product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:30:22.055278+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25542,"accession_number":"0001437749-26-025793","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing UroGen's Q2 2026 financial results, including total revenue of $72.5 million (up from $24.2 million in Q2 2025), ZUSDURI product revenue of $50.4 million with 73% quarter-over-quarter growth, and a net loss of $14.4 million. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's lead product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:30:22.055278+00:00","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-08-05"}]}